Browsing Tag
Novartis Venture Fund
2 posts
Could monthly treatment replace burdensome peanut allergy dosing? Aravax may soon have an answer
Aravax gains FDA Fast Track status for PVX108 as Phase 2 peanut allergy data approach and preparations for a possible Phase 3 program advance.
Tagworks Pharmaceuticals bags $65m in Series A for Click-to-Release technology
Tagworks Pharmaceuticals BV, a Netherlands-based pioneer in Click-to-Release chemistry that promotes more effective and safer systemic therapies, has…